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ABSTRACT 
Chen, Yu-Hsiang. M.S., Purdue University, August 2013. Analysis of Integration Sites of 
Transgenic Sheep Generated by Lentiviral Vectors Using Next-Generation Sequencing 
Technology. Major Professor: Anna Malkova. 
 
 
The development of new methods to carry out gene transfer has many benefits to 
several fields, such as gene therapy, agriculture and animal health[1].  The newly 
established lentiviral vector systems further increase the efficiency of gene transfer 
dramatically.  Some studies have shown that lentiviral vector systems enhance efficiency 
over 10-fold higher than traditional pronuclear injection[2], [3].  However, the timing for 
lentiviral vector integration to occur remains unclear.  Integrating in different stages of 
embryogenesis might lead to different integration patterns between tissues.  Moreover, 
in our previous study we found that the vector copy number in transgenic sheep varied, 
some having one or more copies per cells while other animals having less than one copy 
per cell suggesting mosaicism.  Here I hypothesized that injection of a lentiviral vector 
into a single cell embryo can lead to integration very early in embryogenesis but can also 
occur after several cell divisions.  In this study, we focus on investigating integration 
sites in tissues developing from different germ layers as well as extraembryonic tissues 
to determine when integration occurs.  In addition, we are also interested in insertional 
mutagenesis caused by viral sequence integration in or near 
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gene regions.  We utilize linear amplification-mediated polymerase chain reaction (LAM-
PCR) [4] and next- generation sequencing (NGS) technology[5] to determine possible 
integration sites.  In this study, we found the evidence based on a series of experiments 
to support my hypothesis, suggesting that integration event also happens after several 
cell divisions.  For insertional mutagenesis analysis, the closest genes can be found 
according to integration sites, but they are likely too far away from the integration sites 
to be influenced.  A well-annotated sheep genome database is needed for insertional 
mutagenesis analysis. 
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CHAPTER 1. INTRODUCTION 
1.1 Objectives 
The overall goal of this research was to investigate the integration pattern of lentiviral 
vector after direct injection of lentiviral vectors into single-cell embryo to generate 
transgenic sheep.  So far, no study has demonstrated when the viral vector will integrate 
into host genome.  In a study it was found the vector copy number in transgenic sheep 
varied, which might suggest that integration events happen after several cell divisions 
but can also occur very early potentially at the single cell stage.  Here I hypothesized 
that lentiviral vector injected into a single cell embryo can lead to integration very early 
in embryogenesis but can also occur after several cell divisions.  The integration might 
occur in single-cell stage, resulting in the same integration sites in every organ of the 
animal; it might also take place in the relatively late stage of the embryogenesis, leading 
to different integration sites between organs.  This research is described with respect to 
the following specific aims: 
1. To evaluate the pattern of LAM-PCR product of organs from different germ layers. 
2. To localize exact integration sites by high-throughput sequencing technology. 
3. To compare the integration sites between organs.
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4. To verify the integration sites by conventional PCR. 
5. To examine the genes near integration sites. 
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CHAPTER 2. LITERATURE REVIEW 
2.1 Transgenic Livestock 
Gene transfer technology in animals has been developed for over three decades.  In 
1980, the first transgenic animal was generated by microinjection of foreign DNA into 
pronulcei of embryos.  Since then, microinjection of DNA into zygotes has been a 
popular method to generate transgenic mice[6].  In 1985, the first transgenic livestock 
was generated according to this method for the purpose of expressing human growth 
hormones[7].  The efficiency of generating transgenic livestock, however, was very low 
(1-5%)[8] due to species differences and inherent technical problems[9].  As a result, 
obtaining transgenic animals was not only time-consuming but also very costly[10], [11]. 
 
Many methods have been developed to overcome this shortage, such as sperm 
mediated DNA transfer[12], intracytoplasmic injection of sperm heads carrying DNA[13], 
somatic cell nuclear transfer[14] and injection of viral vectors to embryos[15].  To date, 
a large number of transgenic animal models have been successfully established to study 
mechanisms of human diseases in terms of gene-disease relationships, to evaluate gene 
therapy strategies, and to alter phenotype of farm animals such as increasing growth 
rates[1], [16], [17].  
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Among those methods described above, lentivirus-mediated gene transfer systems have 
become a popular method to accomplish this task due to several features.  They share 
common features with retroviral systems, such as high efficient gene delivery and the 
ability to integrate permanently into host genome, resulting in long-term transgenic 
expression.  Compared to retroviral rectors, lentiviral vectors can carry larger size of 
transgenes which can be up to 10 kilobases(kb)[18].  In addition, lentiviral vectors can 
also infect non-dividing cells[19].  This unique property allows lentiviral vectors to be 
introduced to more tissues, such as retina, brain, liver and muscle[20–22].  Due to the 
high efficiency of utilizing lentiviral vector as a gene transfer vehicle, many kinds of 
transgenic livestock have been generated with high transgenic rate, such as mice[23], 
pigs[9], cattle[15] and chickens[2], [24]. 
 
2.2 Lentiviral Vector 
Lentivirus is one of subfamilies of retrovirus.  The first isolated lentivirus was equine 
infectious anemia virus (EIAV).  Other lentiviruses were subsequently isolated from 
other species, such as feline immunodeficiency virus (FIV) from cat, simian 
immunodeficiency virus (SIV) from nonhuman primates and human immunodeficiency 
virus type 1 (HIV-1) from human[25].  Lentiviral vectors were developed from the 
lentiviruses described above.  Among these lentiviral vectors, the HIV-1-based vector 
system is the one which has been studied and applied the most[26]. 
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As one of the subfamilies of retroviruses, lentiviral vectors share many features with 
retroviruses, such as an RNA genome with gag, pol, and env genes, which code for 
internal structure proteins (capsid), viral enzymes (reverse transcriptase and integrase), 
and envelope glycoproteins, respectively[8].  Usually, the env gene would be replaced 
by vesicular stomatitis virus G protein (VSV-G) gene[27] to broaden host range and to 
stabilize particles that can be concentrated by ultracentrifugation.  Besides this, 
lentiviral vectors have long terminal repeat (LTR) DNA segmented into U3, R, U5 regions, 
located at both ends and required for vector integration.  Second generation lentiviral 
vectors have U3 region of 5' LTR replaced by a cytomegalovirus (CMV) promoter to 
increase transgene expression[28]. 
 
2.3 Safety Concern 
In spite of the advantages of utilizing lentiviral vector as a gene delivery vehicle, there 
are still concerns regarding its safety.  Although some modifications have been made to 
ensure safety in designing lentiviral vectors, such as deleting some HIV genes[29], [30], 
using self-inactivating 3' LTR to eliminate transcriptional ability[31], [32] and separating 
vector components into three to four different plasmids[30], the possibility of 
generating replication competent lentivirus (RCL) due to recombination of plasmids and 
endogenous viral sequences still can not be overlooked.  In addition, the tendency of 
lentiviral vectors to insert sequences semi-randomly into host genome is another 
concern[33].  This tendency would result in either altering the expression level of nearby 
genes or disrupting the function of the host genes if the insertion sites are located in 
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functional domains[19].  Insertional mutagenesis has been observed in trials of X-linked 
severe combined immunodeficiency (SCID-X1) treated with gammaretroviral vectors.  
Several SCID-X1 patients developed leukemia after being treated with gene therapy due 
to the insertion of retroviral vectors into position near LMO2 proto-oncogene promoter, 
leading to abnormal expression of LMO2[34], [35].  Another concern would be the 
transfer of vector sequences to non-target tissues, for example, from transgenic 
embryos to surrogates after embryo transfer[36].  It also could be possible that the 
transgenic cells migrate through placenta during pregnancy or delivery. 
 
In a previous study of transgenic sheep[37], no evidence of RCL had been observed in 
surrogates, fetuses or lambs.  RCL had been evaluated by: (1) p24 ELISA, which is 
performed to screen for HIV-1 viral capsid; (2) high sensitive real-time polymerase chain 
reaction (qPCR) to detect VSV-G envelope, which is used to pseudotype HIV-1 due to its 
ability to infect broader cell types. 
 
In a previous study the vector copy number was also evaluated to quantitate gene 
transfer.  Although the majority of the animals had one or more copies per cell, some 
animals had less than one copy per cell suggesting that there might be mosaicism.  This 
result could occur if the integration happened after several cell divisions.  Based on this 
hypothesis, in this study we focused on identifying lentiviral vector integration sites in 
transgenic sheep fetal tissues.  We evaluated the tissues including placenta and tissues 
derived from three different germ layers.  In addition, we also wanted to further 
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evaluate insertional mutagenesis caused by viral vector integration.  We confirmed the 
location where the lentiviral vectors integrate to see if the integration sites located in or 
near important genes. 
 
To identify the integration sites, we conducted LAM-PCR on both sheep fetal and some 
surrogate tissues.  After performing LAM-PCR, we barcoded samples by different index 
sequences so that we could run multiple samples in one NGS run.  After analyzing 
sequencing data, we verified these integration sites by conventional PCR. 
 
8 
 
8
 
CHAPTER 3. MATERIALS AND METHODS 
3.1 Production of Transgenic Embryos 
For this portion of the experiment we collaborated with a team led by Dr. Westhusin in 
the Departments of Veterinary Physiology and Pharmacology, College of Veterinary 
Medicine, Texas A&M University.  Recombinant lentivirus was produced from second 
generation lentiviral plasmids which contained a green fluorescent protein (GFP) gene 
as described in the paper of Miyoshi et al.[32] with modifications to enhance titer for 
embryo microinjection. 
 
Zygotes were obtained surgically from superovulated donor ewes 24 hours post mating.  
Microinjection was then done by injecting 20 picoliters of High titer (109 particles/ml) 
recombinant lentivirus into perivitelline space of the embryos(Figure 3.1).  After 
injection, the embryos were transferred back to the oviducts of recipient ewes, which 
received 3-4 embryos for each.  At around 70 days of gestation, the pregnant ewe were 
euthanized to collect tissues from fetuses, placenta and surrogate ewes for analysis. 
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Figure 3.1. Schematic figure of embryo injection of lentiviral vectors into perivitelline 
space of one-cell sheep embryo 
 
 
 
 
 
 
 
 
Perivitelline space 
One-cell embryo 
Lentiviral vector 
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3.2 Tissue Collection and DNA Extraction 
Fetuses and surrogate ewes were dissected to collect tissues including heart, liver, lung, 
kidney, intestine, skeletal muscle, skin, gonad, placentome, uterus, interplacentomal 
uterus when available.  Tissues were cut into 3-5 mm pieces and preserved in All Protect 
tissue reagent (QIAGEN, Hilden, Germany). 
 
DNA was extracted using DNeasy Blood & Tissue kit (QIAGEN).  The procedure was as 
follows: tissues were cut up to 25 mg and then put into a 1.5 ml microcentrifuge tube.  If 
tissue weight is heavier than 25 mg, the tissue was separated into more than two tubes.  
To each tube 180 ul of Buffer ATL wad added with 20 ul proteinase K into tube then mix 
thoroughly by vortexing, and incubated at 56 °C until the tissue is completely lysed.  
Added 4 ul RNaes A (100 mg/ml, Qiagen) to tube and mixed by vortexing, then 
incubated at room temperature for 10 minutes.  After this 200 ul of Buffer AL was added 
to a tube and mixed by vortexing.  Then 200 ul of ethanol (98-100%) was added to a 
tube and mixed by vortexing.  The mixture was pipetted into DNease Mini spin column 
placed in a 2 ml collection tube and centrifuged at 8000 rpm for 1 minute.  Discarded 
flow-through and collection tube.  Placed DNease Mini spin column in a new 2 ml 
collection tube, then added 500 ul Buffer AW2, and centrifuged at 14,000 rpm for 3 
minutes.  Discarded flow-through and collection tube.  Placed DNease Mini spin column 
in a new 1.5 ml tube, then added 200 ul Buffer AE, then incubated at room temperature 
for 2 minutes.  Centrifuged at 8000 rpm for 3 minutes to elute DNA. 
11 
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3.3 Integration Analysis 
 
3.3.1 LAM-PCR 
We took 100 ng DNA from each sample according to the concentration measured from 
previous step.  Linear amplification was performed using labeled LTR-specific primer 
(LTR Ib-bio, 5'-gaa ccc act gct taa gcc tca-3').  PCR reaction was set up in 0.2 ml tube that 
contained the following: 5 ul of 10X PCR buffer (Qiagen), 1 ul of 10 mM dNTP, 0.5 ul of 
0.5 uM LTR Ib-bio primer (IDT), 0.5 ul of Taq Polymerase (5 units/ul, Qiagen), 100 ng 
DNA, and ddH2O to make up total volume of 50 ul.  Amplified DNA fragments using the 
following PCR program: denaturation at 95°C for 5 minutes, followed by 50 cycles of 
denaturation at 95°C for 1 minute, annealing at 60°C for 45 seconds, and extension at 
72°C for 1.5 minutes.  A final extension for 10 minutes at 72°C was also included.  1.5 ul 
of ddH2O and 0.5 ul of Taq polymerase were added to each tube, then repeated the 
program above. 
 
20 ul streptavidin-coated magnetic beads (Dynal M-280) was used for each tube to 
capture PCR products with biotin. Then incubated at room temperature on a shaker for 
8-48 hours.  Washed beads with 100 ul ddH2O twice on magnetic stand then discarded 
all liquid in tube. 
 
Second-stranded synthesis was then performed on single-stranded DNA captured on 
magnetic beads.  The reaction was set up as follows: 2 ul of 10X Hexanucleotide Mix 
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(Roche), 0.5 ul of 10 mM dNTP, 1 ul of Klenow polymerase (Roche), and 16.5 ul of ddH2O.  
Tubes were incubated at 37°C for 1 hour.  Beads were washed with 100 ul water twice 
on magnetic stand then discarded all liquid in tube. 
 
DNA was then digested by Tsp509I.  The reaction was set up as follows: 2 ul of 10X 
Restriction Buffer #1 (NEB), 1 ul of Tsp509I (2.5 units/ul, NEB), and 17 ul of ddH2O.  
Tubes were incubated at 65°C for 1 hour.  Beads were washed with 100 ul ddH2O twice 
on magnetic stand then discarded all liquid in tube. 
 
An adaptor cassette (generated by oligonucleotide 5'-gac ccg gga gat ctg aat tca gtg gca 
cag cag tta gg-3' and oligonucleotide 5'-aat tcc taa ctg ctg tgc cac gta att cag atc-3') was 
ligated to the digested end of the captured fragments.  The reaction was set up as 
follows: 1 ul of 10X Incubation Buffer (Epicentre Biotech), 1 ul of ATP (10 mM, Epicentre 
Biotech), 2 ul of Adaptor cassette (Epicentre Biotech), 1 ul of Fast Link' DNA ligase (2 
units/ul, Epicentre Biotech), and 5 ul of ddH2O.  Then incubated at room temperature 
for 30 minutes.  The beads were washed with 100 ul ddH2O twice on magnetic stand 
then discarded all liquid in tube.  Denatured DNA by 5 ul fresh 0.1 N NaOH.  Then 
incubated at room temperature for 30 minutes followed by using magnetic stand to 
transfer 5 ul single-strand DNA to a new 1.5 ml tube. 
 
Nested PCR was then performed.  For the first round of PCR (primers: LTR II-bio, 5'-agc 
ttg cct tga gtg ctt ca-3' and LC1, 5'-gac ccg gga gat ctg aat tc-3'), the reaction and were 
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set up as follows: 5 ul of 10X PCR buffer (Qiagen), 1 ul of 10 mM dNTP, 0.5 ul of 50 uM 
LTR II-bio primer (IDT), 0.5 ul of 50 uM LC1 primer (IDT), 1 ul of Taq Polymerase (5 
units/ul, Qiagen), 2 ul of DNA from previous step, and 40 ul of ddH2O.  Amplified DNA 
fragments using the following PCR program: denaturation at 95°C for 5 minutes, 
followed by 35 cycles of denaturation at 95°C for 1 minute, annealing at 60°C for 45 
seconds, and extension at 72°C for 1.5 minutes.  A final extension for 10 minutes at 72°C 
was also included. 
 
PCR products were captured by 20 ul streptavidin-coated magnetic beads.  Washed by 
100 ul ddH2O twice on magnetic stand.  Discarded all the liquid in tube.  Denatured DNA 
by 20 ul 0.1 N NaOH.  Collected 20 ul denatured DNA to a new 1.5 ul tube then 
proceeded to second round PCR. 
 
For the second round of PCR (primers: LTRIII, 5'-nnn nnn agt agt gtg tgc ccg tct gt-3' and 
LCII, 5'-agt ggc aca gca gtt agg), the reaction was set up as follows: 5 ul of 10X PCR buffer 
(Qiagen), 1 ul of 10 mM dNTP, 0.5 ul of 50 uM LTR III primer (IDT), 0.5 ul of 50 uM LCII 
primer (IDT), 1 ul of Taq Polymerase (5 units/ul, Qiagen), 2 ul of DNA from previous step, 
and 40 ul of ddH2O.  PCR program was the same as first round PCR.  The resulting 
products were visualized by gel eletrophoresis. 
14 
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Figure 3.2. Schematic figure of LAM-PCR. Linear PCR was performed to amplify vector-
genome junction region; PCR products were converted to double-stranded, followed by 
restriction enzyme digestion.  Later, linker cassette was ligated to introduce known 
sequence to the other end of fragments.  Nested PCR was performed to amplify the 
signal so that LAM-PCR products could be seen on a gel. 
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3.3.2 Next Generation Sequencing and Reads Processing 
To sequence LAM-PCR products, individually bar-coded amplicon libraries were 
generated by using forward fusion primers containing different indices during round 2 
nested PCR (Figure 3.3; Table 3.1).  Samples were pooled and sequenced on Illumina 
Miseq instrument by our collaborator in University of Notre Dame.  Barcodes and vector 
sequences were removed from the reads.  The rest of the sequence of reads were 
mapped onto aligning regions in the sheep genome (oviAri1, UCSC Genome Database).  
Each integration locus was re-examined manually and PCR was done to verify accuracy. 
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Figure 3.3. Schematic figure of introducing index by fusion primer.  Six to eight bases 
indices were designed at the 5’ end primers of round 2 nested PCR.  While performing 
round 2 nested PCR, the first index could be introduced to the LTR end of the amplicon.  
Second index could be introduced during library preparation.  P5 and P7 are the 
sequences required for next generation sequencing. 
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Table 3.1. Index sequence corresponding to different animals and tissues 
 
 
 
 
 
 
 
 
 
 
 
 
Animal Organ Index Sequence 
498-1 Kidney AGTTCC 
 Skin ATGAGC 
 Placenta CGCGTC 
 Intestine GATACA 
714-1 Lung AAGCCGC 
 Kidney CAAGAAC 
 Skin TGACGAC 
709-1 Kidney GGTAGC 
 Placenta TCATTC 
 Liver ATCTTAC 
 Skin TGGTCT 
709-2 Intestine CTCTCTAT 
 Uterus TATCCTCT 
 Placentome AGAGTAGA 
 Kidney AAGGAGTA 
 Skin TGTCGT 
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CHAPTER 4. RESULTS 
4.1 Evaluating the Pattern of LAM-PCR Product from Different Germ Layers 
In order to test my hypothesis that the integration can occur after multiple cell divisions, 
we chose LAM-PCR to evaluate integration sites in organs from different germ layers.  
LAM-PCR is the common technique for finding integration sites by amplifying the vector-
genome junction region.  Compared to other methods to track vector insertion sites, 
such as inverse PCR (IPCR) and ligation-mediated PCR (LM-PCR), LAM-PCR is more 
sensitive such that the requirement for DNA amount is very low (down to 0.01 ng) for 
each reaction.  LAM-PCR utilizes restriction enzymes resulting in uniquely sized band for 
each integration site.  The products of LAM-PCR can then be visualized on a gel.  We can 
see if there is any different integration site by comparing the LAM-PCR product pattern 
of each organ. Here we should state that in every LAM-PCR reaction, there will be one 
internal control band been seen on a gel since the primers used in LAM-PCR was 
designed to anneal to LTR region, which is identical on both sides of provirus (Figure 4.1).  
In this study, we conducted LAM-PCR on four transgenic sheep fetuses, which consisted 
of 34 tissue samples. 
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Figure 4.1. Simplified schematic figure of provirus structure.  In order to get close to 
genomic sequence, primers were designed on LTR region, resulting in two kinds of 
products: (1) internal control sequence, and (2) vector-genome sequence. 
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In 709-1(Figure 4.2), we observed that all tissues shared the same pattern with three 
major bands except interplacentomal uterus sample, which was not part of fetal tissues.  
In 709-2(Figure 4.3), the product patterns of uterus and placentome were different from 
other samples.  These differences were expected because they were not fetal tissues.  In 
animal 498-1 (Figure 4.4), all tissues shared the same pattern that with three major 
bands in between 200 to 300 bp in size.  In animal 714-1(Figure 4.5) we found that all 
tissues shared the same pattern to each other.  Although there was only one major 
band observed in this animal, there were several faint bands in some tissues, which 
might indicate other possible integration sites.  In this LAM-PCR experiment, we did not 
see any different pattern among fetal tissues in the same animal, indicating that there 
were common integration sites in all tissues we examined in the same animal.  This 
might suggest that integration occurred potentially at single-cell stage.  Further 
investigation of exact integration sites is required to confirm this hypothesis. 
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Figure 4.2. 
LAM-PCR products of transgenic sheep fetal tissues-animal 709-1.  (1)interplacentomal 
uterus, (2)liver, (3)placenta, (4)placentome, (5)gonad, (6)kidney, (7)heart. 
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Figure 4.3. LAM-PCR products of transgenic sheep fetal tissues-animal 709-2.  (1)lung, 
(2)intestine, (3)uterus, (4)placentome, (5)heart, (6)liver, (7)kidney. 
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Figure 4.4. LAM-PCR products of transgenic sheep fetal tissues-animal 498-1.  
(1)intestine, (2)placenta, (3)skin, (4)testis, (5)skeletal muscle, (6)lung, (7)liver, (8)kidney, 
(9)heart. 
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Figure 4.5. LAM-PCR products of transgenic sheep fetal tissues-animal 714-1.  (1)heart, 
(2)liver, (3)lung, (4)kidney, (5)intestine, (6)skeletal muscle, (7)testis, (8)blood. 
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4.2 Localizing Exact Integration Sites by High-Throughput Sequencing Technology 
In order to further identify the exact location of the integration sites, we utilized high-
throughput sequencing technology.  Among many platforms, we chose Miseq, launched 
by Illumina, to carry out this work.  Miseq is a powerful platform that can yield 
sequences up to 2 Giga bases per run.  In addition, the low error rate (0.8 %) is another 
attractive feature.  Moreover, up to 96 samples can be run at once when samples are 
barcoded.  This is the main reason why we chose Miseq as the high-throughput 
sequencing platform.   
 
Among these LAM-PCR products, we collected samples with different patterns as well as 
samples derived from different germ layers.  In order to add barcodes to DNA samples, 
we performed PCR using primers with different barcodes on intermediate products in 
the step before final exponential PCR in LAM-PCR.  After quantifying, we mixed the 
same amount (100 ng) of final PCR products into one tube for next-generation 
sequencing.  The library preparation, cluster generation and sequencing were done by 
our collaborator at the University of Notre Dame. 
 
4.3 Comparing the Integration Sites between Organs 
After getting sequencing data back, we sorted sequencing reads by barcodes to identify 
the data for a specific sample.  We removed the reads without LTR sequence in the 5' 
end of the reads, which might have been the product of non-specific amplification.  In 
order to get the genome sequence adjacent to vector sequence, we trimmed LTR 
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sequences as well as adapter sequences that were added in by the LAM-PCR experiment.  
To identify the integration sites, we applied “BLAT” using qualified reads against sheep 
genome database (version: oviAri1) on UCSC genome browser.  Here we listed the top 
two groups of sequencing reads of every sample we sent for sequencing (Table 4.1). 
 
For 709-1, the most abundant group of reads in all the tissues except interplacentomal 
uterus could be mapped to Chromosome 8 with 94% identity.  For 709-2, the reads of 
intestine, kidney and skin could be mapped to Chromosome 1 with 100% identity.  For 
uterus in 709-2, although the most abundant group of reads could be mapped to ChrX: 
76405016, the undefined sequences (“N” base) near this position indicated this region 
of sheep genome was not well confirmed by enough sequencing data. 
 
In animal 498-1, we found that the most abundant group of reads (from 33% to 55%) in 
every tissue could not be mapped to any genomic region in database.  The second 
abundant group of reads had lower identity (81%) against the position ChrX: 50970245.  
Animal 714-1, 709-1 and 709-2 also had high percentages of reads with low identity 
against the same position as 498-1.  Since the integration of lentiviral vectors is 
relatively random, it was less likely that these four animals had the same integration site.  
In addition, the reads with low identity against position ChrX:50970245 also suggested 
that these reads might be the result of non-specific amplification.   
For animal 714-1, we observed the same phenomenon as 498-1 that the same group of 
reads in all the samples could not be mapped to genome.  The result indicated that the 
27 
 
2
7 
integration sites were the same in tissues derived from different layers of the same 
animal.  In addition, the sheep genome database is not well-developed so that some of 
our samples had integration sites but the exact location of the integration could not be 
mapped to the genome. 
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Table 4.1. Potential integration sites in different tissues of each animal 
498-1 Hyp. IS # of reads % of Total Chromosome Position Identity 
Kidney 
IS1 55144 55.24  no match  
IS2 13820 13.84 X 50970245 81% 
Skin 
IS1 21912 33.56  no match  
IS2 10638 16.29 X 50970245 81% 
Placenta 
IS1 7781 52.02  no match  
IS2 2320 15.51 X 50970245 81% 
Intestine 
IS1 13105 41.22  no match  
IS2 5070 15.95 X 50970245 81% 
       
       
714-1 Hyp. IS # of reads % of Total Chromosome Position Identity 
Lung 
IS1 75033 65.39 X 50970245 81% 
IS2 8710 7.59  no match  
Kidney 
IS1 37089 59.43 X 50970245 81% 
IS2 4727 7.57  no match  
Skin 
IS1 22788 68.99 X 50970245 81% 
IS2 2780 8.42  no match  
       
       
709-1 Hyp. IS # of reads % of Total Chromosome Position Identity 
Kidney 
IS1 11312 45.48 8 23921255 94% 
IS2 3812 15.33 X 50970245 81% 
Placenta 
IS1 11037 48.67 8 23921255 94% 
IS2 3407 15.02 X 50970245 81% 
Inter uterus 
IS1 5306 23.37 X 50970245 81% 
IS2 3507 15.44  no match  
Skin 
IS1 13105 41.22 8 23921522 94% 
IS2 5070 15.95 X 50970245 81% 
       
 
 
 
 
 
 
      
29 
 
2
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1. Cont. 
 
709-2 Hyp. IS # of reads % of Total Chromosome Position Identity 
Intestine 
IS1 1189 16.9 X 50970245 81% 
IS2 1095 15.57 1 26891712 100% 
Uterus 
IS1 50703 52.28 X 76405016         * 
IS2 10068 10.38 X 50970245 81% 
Placentome 
IS1 7361 19.63 X 50970245 81% 
IS2 5577 14.87   no match   
Kidney 
IS1 12161 16.49 1 26891712 100% 
IS2 11106 15.06 X 50970245 81% 
Skin 
IS1 3085 19.38 X 50970245 81% 
IS2 2512 15.78 1 26891712 100% 
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4.4 Verifying the Integration Sites by Conventional PCR 
In order to confirm the integration sites we found from NGS data, we designed the 
primers for PCR that were located near (several hundred bases away) possible 
integration site (Table 4.2).  After finding possible integration sites in tissue samples, we 
performed PCR on all available samples in the same animal.  For the hypothetical 
common integration site in all four animals, we did not see any amplified PCR product 
on gel (data not shown).  Despite the identity of the integration site on Chromosome 8 
in 709-1 is only 94%, we could still observe the expected band (579 bp) in all the tissues 
except interplacentomal uterus (Figure 4.6, Table 4.3).  We could also observe the 
expected band (487 bp) in all tissues except uterus and placentome of 709-2 (Figure 4.7, 
Table 4.3).  Besides this, we also conducted PCR on 709-2's another integration site we 
found in a previous study, and the expected band (288 bp) could also be seen in all 
tissues except uterus (Fig. 4.8, Table 4.3).  In addition, we also screened the integration 
sites which could be found in other animals (411-1, 536-1) in previous study.  PCR 
product of all tissues of 411-1 could be observed (435 bp)(Figure 4.9, Table 4.3).  
Interestingly, in 536-1 we found that there were two bands in the placenta sample and a 
single band in other samples (Figure 4.10).  The unique band in placenta was 
expected(372 bp), but not the band that appeared in all tissues. 
 
31 
 
3
1 
Table 4.2. Confirmation primer list 
 
Animal Chromosome Strand Position Confirmation Primer Sequence 
Expected 
Length (bp) 
714-1 ChrX + 50970245 TCTTAGCATATAATCAGGCAATGG 252 
709-1 Chr8 + 23921254 GGTCCTGAGGGGAGTATGGT 579 
709-2 Chr1 + 26891711 TGGGAAAACTGAGGATTTGG 487 
709-2 ChrX - 83102460 GTGTCAAGACCCGGTAGGAA 288 
411-1 Chr6 - 125302589 GGAAGACTCTGGGAGTGCTG 435 
536-1 Chr4 + 49573928 ATTTAAGGCGGGGGTTCAGT 372 
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Figure 4.6. PCR to confirm integration site-animal 709-1.  (1)heart, (2)kidney, (3)skin, 
(4)gonad, (5)placentome, (6)placenta, (7)liver, (8)interplacentomal uterus, (9)negative 
control. 
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Figure 4.7. PCR to confirm integration site-animal 709-2(IS1).  (1)lung, (2)intestine, 
(3)skin, (4)placenta, (5)uterus, (6)placentome, (7)heart, (8)liver, (9)kidney, (10)negative 
control. 
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Figure 4.8. PCR to confirm integration site-animal 709-2(IS2).  (1)lung, (2)intestine, 
(3)skin, (4)placenta, (5)uterus, (6)placentome, (7)heart, (8)liver, (9)kidney, (10)negative 
control. 
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Figure 4.9. PCR to confirm integration site-animal411-1.  (1)heart, (2)liver, (3)lung, 
(4)kidney, (5)intestine, (6)skin, (7)placenta, (8)negative control. 
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Figure 4.10. PCR to confirm integration site-animal 536-1.  (1)heart, (2)lung, (3)skeletal 
muscle, (4)gonad, (5)intestine, (6)negative control. 
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Table 4.3. Integration sites confirmed by conventional PCR 
      Sk.       Inter.   
Animal Heart Liver Lung Kidney Intestine Muscle Skin Gonad Blood Placenta Placentome uterus Uterus Chr. Position 
498-1 - - - - - - - - NA - NA NA NA X 50970245 
714-1 - - - - - - - - - NA NA NA NA X 50970245 
709-1 + + NA + NA NA + + NA + + NA - 8 23921255 
709-1 - - NA - NA NA - - NA - - NA - X 50970245 
709-2 - - - - - NA - NA NA - - - NA X 50970245 
709-2 + + + + + NA + NA NA + - - NA 1 26891712 
709-2 + + + + + NA + NA NA + + - NA X 83102460 
                
411-1 + + + + + NA + NA NA + NA NA NA 6 125302589 
536-1 - NA - NA NA - NA - NA + NA NA NA 4 49573928 
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4.5 Examining the Genes near Integration Sites 
In order to examine for possible bias in the site of integration, we searched sheep 
database to compare integration site in different animals.  Since one of 709-2 
integration sites is on Chromosome X, which has no gene information on the database, 
we could not tell if this integration site was located in a gene region.  Then, we searched 
the genes closest to integration sites from either direction.  We found that all of the 
genes were very far away from integration sites (> 2 Mega bases), suggesting that the 
provirus would not influence expression of those genes (Table 4.4).  We need to notice, 
however, that there might be some genes located even closer to integration site but not 
yet annotated in the sheep genome database. 
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Table 4.4. Gene ontology analysis of confirmed integration sites 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Animal Chromosome Strand Position   Gene name Strand Position Distance 
411-1 chr6 - 125302589 
  RAB28 - 123049372 2.3 MB 
  CNO + 127642942 2.3 MB 
536-1 chr4 + 49573928 
  RPL23A - 45570293 4 MB 
  SLC26A3 - 51618165 2 MB 
709-1 chr8 + 23921254 
  ASF1A - 21684001 2.2 MB 
  FOXO3 - 31032239 7.2 MB 
709-2 chr1 + 26891711 
  UQCRH + 20795962 6.1 MB 
  PRKAA2 + 31664555 4.8 MB 
709-2 chrX - 83102460      N/A 
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CHAPTER 5. DISCUSSION 
The applications of gene transfer technology to farm animals have many benefits to 
agriculture and animal health.  Recently developed lentiviral vector systems can 
undoubtedly contribute to this field dramatically due to their high efficient gene transfer.  
Many studies have proven that utilizing lentiviral vectors as delivery vehicles can 
increase the efficiency from several folds even up to several tens of times[2].  The major 
concern of applying this technology is safety.  In previous studies[37] in our lab, it has 
been confirmed that there is no RCL observed in transgenic fetuses, lambs as well as 
surrogate mothers.  However, the timing for integration event to occur after 
microinjection remains mysterious.  We evaluated the vector copy number analysis and 
found that although the majority of animals had one or more copy numbers, some 
animals had less than one copy.  This phenomenon implies that the vector integration 
might occur after several cell divisions at least in some animals.   
 
To confirm our hypothesis, we selected four animals with different copy numbers (498-1: 
0.4 copier/cell; 714-1: 0.45 copier/cell; 709-1: 3 copier/cell; 709-2: 1.3 copier/cell) 
calculated based on qPCR result to perform LAM-PCR.  The preliminary data of LAM-PCR 
products on the gel showed no difference between fetal tissues in each animal.  This 
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indicated that the integration event happened in an early stage, especially for 709-1 and 
709-2 that it might occur in one-cell embryo stage. 
 
We further collected LAM-PCR products for next-generation sequencing to find out the 
integration sites in each animal.  In the integration site analysis, we found the all four 
animals had a high proportion of reads against the position ChrX: 50970245, suggesting 
that this might be the result of non-specific amplification against homologous sequences 
on sheep genome.  We confirmed this hypothesis by PCR using primer annealing to this 
region along with vector primer.  No PCR product was observed.  For the other possible 
integration sites which were able to be analyzed, only one integration site with an 
identity higher than 90% could be found in animal 709-1 and 709-2, which is different 
from the copy number (709-1: 3 copier/cell; 709-2: 1.3 copier/cell) we observed in qPCR 
result of a previous study.  It should be stated here that the LAM-PCR method had some 
limitations that should be considered when explaining our data.  First, the use of 
restriction enzyme; LAM-PCR utilizes restriction enzyme to cut the flanking genomic 
sequence outside the vector sequence.  If the flanking sequence is too short (<20 bp) 
after cutting, the length of the sequence would be insufficient to identify genomic 
location.  If the distance of the restriction site is too far from the LTR-genomic junction 
the amplification reaction would likely not reach the genomic cut site and the fragment 
would not be amplified[38].  Secondly, the biased distributions of CpG in mammalian 
DNA is another factor to influence discovery of integration site by LAM-PCR.  The 
percentage of GC content near integration site will influence restriction enzyme 
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efficiency as well as the PCR efficiency[39].  In addition, the PCR efficiency will also be 
influenced by inverted repeat sequences within the amplicon[40].  These limitations all 
influence the detection of an integration site, so that only a portion of integration sites 
can be found when utilizing LAM-PCR. 
 
Nevertheless, both integration sites in 709-1 and 709-2 can be confirmed by PCR (Figure 
4.6, 4.7).  In addition, another integration site in 709-2 had been found in a previous 
study has also been confirmed by PCR in this study (Figure 4.8).  Since the copy number 
is greater than 1 copy per cell and the integration sites can be detected in all fetal 
tissues and the placenta, this finding suggesting that the integration occurred early in 
embryogenesis, possibly at the one-cell embryo stage. 
 
Furthermore, we also verified integration sites in two other animals (411-1, 536-1) 
which had been found in a previous study.  Although in 411-1 we can detect integration 
site in all fetal tissues, the copy number (1 copy/10 cells) estimated by previous qPCR 
result suggested that the integration occurred after several cell divisions and led to 
mosaicism.  Interestingly, we found that in animal 536-1 (Figure 4.10) there were two 
bands from the placenta tissue but only one band in other tissues.  Based on the size of 
plasmid we used to transduce cells, it is less likely that there were two integration sites 
so close to each other.  We then analyzed these two bands by Sanger sequencing.  We 
found that the larger band was a false negative since the BLAST result showed that the 
primers we used had homologous sequences within the target region and the size of 
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this region was similar to the PCR product on gel (~850 bp, Figure 5.1).  We later 
analyzed the smaller band.  We found that this was the true integration site and solely 
in placenta.  In mammalian development, embryonic cells separate into two groups of 
cells-the inner cell mass and trophectoderm, the latter will give rise to placenta after 
implantation[41].  This might be able to explain why in 536-1 only placenta had this 
integration site.  This result supports my hypothesis that lentiviral vector integration can 
also occur after several cell divisions.  Another study to generate transgenic rabbits by 
lentiviral vectors also supported this hypothesis[42].  They observed that the transgenic 
founder rabbits showed mosaic pattern of transgene expression.  It should be noticed 
that in the early embryonic development of a rabbit it took only 11 hours after 
fertilization to reach 4-cell embryo stage, compared to rodent, sheep, swine and 
monkey embryos for which it took 30-40 hours.  The phenomenon of mosaic transgenic 
founder rabbits combined with rapid early embryonic development might suggest that 
the transgene integration occurred in certain time after fertilization, probably after 
several cell divisions. 
 
For gene ontology analysis, although we found some genes are cancer-related genes, 
the distance between integration sites and genes are too far away for any interaction to 
be considered.  There should be some genes located closer to the integration sites and 
the closest genes identified in our analysis, but these were not evident due to the 
incomplete annotation of the sheep genome.  A well-annotated sheep genome 
database is needed for more accurate gene ontology analysis.
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Figure 5.1. Primers homology sequence on sheep genome.  The homology sequence of 
primers to genome led to false positive result of confirmation PCR. 
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In summary, LAM-PCR and sequencing data identified a common integration in the 
tissues of the animals studied, each integration site being unique for each animal.  In 
certain animals (709-1 and 709-2) it appears that integration occurred shortly after 
injection into the single cell embryo.  Our finding in animal 411-1 and 536-1 supported 
the hypothesis that the integration can also occurs after several cell divisions.  It should 
be taken into consideration that the mosaicism means that only a portion of the cells 
will contain the vector and if the desired phenotype requires all of the offspring to 
express the vector then careful screening will be required to insure all cells in the animal 
contain the vector.  This is particularly important if the animal is used to generate 
offspring (founder animal) to ensure the animal carries the transgene of interest in germ 
line cells.  We also know from human gene therapy work that vector can integrate 
preferentially into different gene regions and can influence surrounding gene expression.  
The stage of differentiation (hematopoietic stem cells versus differentiated T cells) also 
influence the effect integration may play on altering cell growth.  To determine if 
lentiviral vectors have a preferential site of integration, or how they alter cell growth in 
an embryo, additional animals and improved annotation of the sheep genome database 
will be required. 
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